Human Metabolome Technologies

Basic Information

Stock Code
6090
Industry
Service Industry
Category Detail
Biotechnology & Pharmaceuticals
Prefecture
Yamagata Prefecture
Establishment Year
July 2003
Listing Year
December 2013
Official Website
https://humanmetabolome.com/jpn/
TSE Information
TSE Information
Yahoo! Finance
Yahoo! Finance
Other Companies
Kojin Bio, Linical, Transgenic Group, Shin Nippon Science, DNA Chip Research, Techmira, H.U. Group Holdings, Falco Holdings, BML, PhoenixBio, Sports F, CS-C

Overview

Human Metabolome Technologies is a cutting-edge bio-service company founded in 2003 as a Keio University spin-off venture, specializing in contracted metabolome analysis using CE-MS technology and biomarker development.

Current Situation

Human Metabolome Technologies is a company with standalone sales of approximately 900 million yen and consolidated sales of approximately 900 million yen as of 2023, centering on contracted metabolome analysis and biomarker business. Since its founding, backed by collaboration with Keio University, it has leveraged its proprietary CE-MS technology to hold high expertise in the metabolome contracted analysis market. Its main customers are domestic and international pharmaceutical companies and research institutions, offering a variety of analysis services, with a particular focus on blood biomarker discovery and diagnostic kit development in the depression field. It is also advancing global expansion through its U.S. subsidiary and biomedical business. In recent years, through capital and business alliances with companies like M3, it aims to create synergies in the medical field and shift to the commercialization phase in pharmaceutical and diagnostic markets. Moving forward, it anticipates growth centered on technological innovation and medical applications of biomarkers, while promoting social contributions as a regional company based in Yamagata.

Trivia

Interesting Facts

  • The company that first put metabolome analysis using CE-MS into practical use worldwide.
  • Famous as a bio-venture from Keio University.
  • Gained attention for successfully discovering blood biomarkers for depression.
  • Representative example of an advanced technology company headquartered in Tsuruoka City, Yamagata Prefecture.
  • Has a U.S. subsidiary and is promoting overseas expansion.
  • Utilizes technology co-developed with Agilent Technologies.
  • Expanding business through capital and business alliances with multiple pharmaceutical companies.
  • Revolutionary technology capable of simultaneous measurement of blood metabolites in 30 minutes.
  • Hosts children's science experiment classrooms, contributing to science education.
  • Holds patented biomarker technology.
  • Capable of high-sensitivity simultaneous detection of dozens of metabolites.
  • Possesses technology nearing practical use in development of medical diagnostic kits.
  • Founder Tomoyoshi Soga is the inventor of CE-MS technology.
  • Consolidated subsidiaries include U.S. subsidiary and domestic biomedical company.
  • Selected for the Ministry of Economy, Trade and Industry's Top 20 University Spin-off Ventures.

Hidden Connections

  • Deep research collaboration with Keio University Institute for Advanced Life Sciences.
  • Technical cooperation with Agilent Technologies in metabolomics field.
  • Provides biomarker technology influencing pharmaceutical companies' diagnostic drug development.
  • As a regional company, has capital alliances with Yamagata Bank and Shonai Bank to support regional economic revitalization.
  • Strengthened collaboration with medical networks through capital and business alliance with M3.
  • Enables global research and technology sharing through establishment of U.S. subsidiary.
  • Contributes to nurturing next-generation scientists through children's science experiment classrooms.
  • Discovery of blood markers for depression diagnosis serves as a bridge to medical diagnostics field.

Future Outlook

Growth Drivers

  • Advancement of CE-MS technology and expansion of outsourced analysis market.
  • Progress in practical application of biomarkers in medical diagnostics.
  • Strengthened expansion into global pharmaceutical development market.
  • Value enhancement through integration with AI and data analysis technologies.
  • Enhanced collaboration with domestic and international pharmaceutical companies and new R&D.
  • New product launches accompanying growth in diagnostic kit market.
  • Improved corporate trust through regionally rooted CSR activities.
  • Competitive strengthening through innovative R&D investments.
  • Market expansion from regulatory easing and new technology approvals.
  • Active utilization of biomarker-related patents.
  • Expansion of service provision to diverse customer segments.
  • Talent securing and technology succession through researcher education support.

Strategic Goals

  • Achieve 30% world market share centered on CE-MS technology.
  • Expand introduction of biomarker diagnostic kits into medical settings.
  • Reach consolidated global sales of approx. 5 billion yen.
  • Develop services incorporating AI analysis technology.
  • Strengthen sustainable regional contributions and social responsibility.
  • Acquire and expand utilization of new technology patents.
  • Establish multifaceted R&D partnerships.
  • Deepen collaboration with diagnostic drugs and medical equipment industry.
  • Implement diversity promotion for employees and next-generation nurturing plans.
  • Promote environmental impact reduction and sustainable bio-technologies.

Business Segments

Services for Research Institutions and Universities

Overview
Provides contracted metabolome analysis and technology for research and development.
Competitiveness
Pioneering practical application of CE-MS technology and high-precision data provision
Customers
  • University Labs
  • Public Research Institutions
  • Pharmaceutical Company Research Labs
  • Bio Ventures
Products
  • Contracted Metabolome Analysis
  • Data Analysis Support
  • Joint Research Programs
  • Technology Licensing

Services for Diagnostic Drug and Biomarker Development Companies

Overview
Supports biomarker discovery for medical diagnostics and drug discovery applications.
Competitiveness
Competitive edge through proprietary biomarker development and patented technology
Customers
  • Diagnostic Kit Manufacturers
  • Pharmaceutical Companies
  • Medical Institutions
Products
  • Biomarker Discovery
  • Clinical Analysis Outsourcing
  • Diagnostic Support Solutions

Manufacturing and Technical Support Business

Overview
Provides technical support and analysis kits for CE-MS instruments.
Competitiveness
Specialized support system in collaboration with instrument manufacturers
Customers
  • Analytical Instrument Users
  • Technology Development Companies
Products
  • Metabolomics Kits
  • Instrument Analysis Support
  • Technical Training

Services for Overseas Subsidiaries

Overview
Provides analysis services globally through its U.S. subsidiary.
Competitiveness
Rapid response and on-site support through local subsidiaries
Customers
  • North American Research Institutions
  • Overseas Pharmaceutical Companies
Products
  • Contracted Analysis
  • Joint Research
  • Local Support

Regional Collaboration and Education Support Business

Overview
Develops venues and provides support for regional revitalization and next-generation nurturing.
Competitiveness
Strong ties with local community and commitment to social contributions
Customers
  • Local Governments
  • Educational Institutions
  • Local Companies
Products
  • Science Education Programs
  • Young Researcher Support
  • Regional Collaborative Research

Competitive Advantage

Strengths

  • High-precision metabolome analysis using proprietary CE-MS technology
  • Strong research collaboration with Keio University
  • Proven track record in biomarker development in specific fields
  • International expansion including U.S. subsidiary
  • Holds advanced patented technologies
  • Team of highly specialized researchers and engineers
  • Years of joint research experience
  • Leading position in diagnostic kit development
  • Trust as a regionally rooted company
  • Experience in capital alliances with various pharmaceutical companies
  • High-quality analysis outsourcing service system
  • Comprehensive technical support
  • Education support programs for researchers
  • Services tailored to customer needs
  • High-level data analysis capabilities

Competitive Advantages

  • World's only service providing metabolome outsourcing analysis using CE-MS
  • Strong foundation from technology development and entrepreneurship by Keio University researchers
  • Advancing discovery of depression biomarkers and practical application of diagnostic kits
  • Broad market expansion through joint research and capital/business alliances with domestic and international pharmaceutical companies
  • Accelerated global expansion with establishment of U.S. subsidiary
  • Imitation countermeasures and technology superiority through active use of patented technologies
  • Steady increase in outsourcing orders through reliability ensured by high-precision data
  • Expansion of analysis kits through collaboration with manufacturing instrument makers
  • Improved corporate image through CSR activities in collaboration with local community
  • Versatile application capabilities leveraging proprietary analysis know-how
  • Supports enhancement of customer engineers' capabilities through advanced technical training programs
  • Potential in licensing business specialized in diagnostics
  • Technology that balances shortened analysis time and high detection sensitivity
  • Systems for securing and developing excellent R&D talent
  • Realization of long-term investments through sound financial base

Threats

  • Price pressures from intensifying competition in bio-pharmaceutical market
  • Risk of technological obsolescence due to emergence of new analysis technologies
  • Delays in diagnostic kit approval and adoption due to stricter regulations
  • Impacts from legal regulations and cultural differences in overseas expansion
  • Risk of reduced R&D investment by major customers
  • Decline in outsourcing analysis share due to alternative technologies
  • Costs of maintaining patent rights and risks of infringement
  • Potential decline in technological strength due to talent outflow
  • Risk of changes in management policies of capital/business alliance partners
  • Risk of production facility shutdown due to natural disasters, etc.
  • Business impacts from strengthened data privacy regulations
  • Uncertainty in market acceptance of research outcomes commercialization

Innovations

2023: Advancing Practical Application of Depression Biomarker Diagnostic Kit

Overview
Progressing development of diagnostic kit using blood ethanolamine phosphate as indicator.
Impact
Improves diagnostic efficiency and promotes application in medical settings.

2022: Enhanced Sensitivity and Shortened Analysis Time for CE-MS Technology

Overview
Improved analysis instrument technology to enhance metabolite detection accuracy and processing speed.
Impact
Achieved increase in outsourcing analysis orders and cost reductions.

2021: Expansion of Overseas Analysis Services

Overview
Strengthened contracted analysis in North American market centered on U.S. subsidiary.
Impact
Sales growth and acquisition of global customers.

2020: Launch of Metabolomics Analysis Support Kit Sales

Overview
Introduced analysis efficiency kits compatible with CE-(Q)TOF MS to the market.
Impact
Enhanced customer instrument analysis capabilities and satisfaction.

Sustainability

  • Ongoing implementation of regionally rooted education support programs
  • Business process improvements aimed at reducing environmental impact
  • Promoting contributions to medicine through next-generation technology development
  • Promoting active roles for female researchers and respecting diversity
  • Strengthening contributions to regional economic revitalization